(TBPH) Theravance Biopharma - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 825m USD | Total Return: 90.5% in 12m

Stock Respiratory Medicine, Drug Development, Therapeutics
Total Rating 40
Safety 32
Buy Signal 0.31
Biotechnology +3.6
Pharmaceuticals +2.0
Market Cap: 825m
Avg Trading Vol: 8.68M USD
ATR: 4.54%
Peers RS (IBD): 50.0
Risk 5d forecast
Volatility44.7%
Rel. Tail Risk-19.5%
Reward TTM
Sharpe Ratio1.26
Alpha60.49
Character TTM
Beta0.919
Beta Downside2.185
Drawdowns 3y
Max DD35.74%
CAGR/Max DD0.39
EPS (Earnings per Share) EPS (Earnings per Share) of TBPH over the last years for every Quarter: "2021-03": -1.24, "2021-06": -0.8, "2021-09": -0.48, "2021-12": -0.43, "2022-03": -0.22, "2022-06": -0.09, "2022-09": -0.21, "2022-12": -0.15, "2023-03": -0.35, "2023-06": -0.28, "2023-09": -0.17, "2023-12": -0.17, "2024-03": -0.24, "2024-06": -0.28, "2024-09": -0.059, "2024-12": -0.0501, "2025-03": -0.1734, "2025-06": -0.0842, "2025-09": 0.07, "2025-12": 0.059, "2026-03": 0,
EPS CAGR: 7.82%
EPS Trend: 64.8%
Last SUE: 0.14
Qual. Beats: 0
Revenue Revenue of TBPH over the last years for every Quarter: 2021-03: 14.257, 2021-06: 12.914, 2021-09: 13.194, 2021-12: 14.946, 2022-03: 13.196, 2022-06: 11.05, 2022-09: 12.451, 2022-12: 14.649, 2023-03: 10.417, 2023-06: 13.749, 2023-09: 15.693, 2023-12: 17.565, 2024-03: 14.503, 2024-06: 14.256, 2024-09: 16.868, 2024-12: 18.754, 2025-03: 15.388, 2025-06: 26.195, 2025-09: 19.99, 2025-12: 45.891, 2026-03: null,
Rev. CAGR: 39.43%
Rev. Trend: 79.9%
Last SUE: -0.97
Qual. Beats: 0
Description: TBPH Theravance Biopharma

Theravance Biopharma, Inc. (TBPH) is a U.S.-based biopharmaceutical company focused on drug development and commercialization.

The company markets YUPELRI, a treatment for Chronic Obstructive Pulmonary Disease (COPD). COPD is a progressive lung disease affecting millions globally. TBPH also has a late-stage drug candidate, Ampreloxetine, for neurogenic orthostatic hypotension (nOH) associated with Multiple System Atrophy (MSA).

Theravance Biopharma operates under a business model common in the pharmaceutical sector, involving both direct commercialization and strategic partnerships, such as its collaboration with Viatris Inc. for YUPELRI.

Further analysis on valuation and financial performance can be found on ValueRay.

Headlines to Watch Out For
  • YUPELRI sales growth drives revenue
  • Ampreloxetine clinical trial results impact valuation
  • Regulatory approval for new indications expands market
  • Collaboration revenue from Viatris Inc. boosts income
Piotroski VR‑10 (Strict) 4.0
Net Income: 105.9m TTM > 0 and > 6% of Revenue
FCF/TA: 0.49 > 0.02 and ΔFCF/TA 52.47 > 1.0
NWC/Revenue: 353.8% < 20% (prev 200.3%; Δ 153.4% < -1%)
CFO/TA 0.49 > 3% & CFO 238.5m > Net Income 105.9m
Current Ratio: 10.93 > 1.5 & < 3
Outstanding Shares: last quarter (53.1m) vs 12m ago 7.60% < -2%
Gross Margin: 94.87% > 18% (prev 0.54%; Δ 9.43k% > 0.5%)
Asset Turnover: 25.59% > 50% (prev 18.18%; Δ 7.42% > 0%)
Interest Coverage Ratio: -0.78 > 6 (EBITDA TTM 827k / Interest Expense TTM 2.46m)
Altman Z'' -5.45
A: 0.78 (Total Current Assets 418.5m - Total Current Liabilities 38.3m) / Total Assets 485.6m
B: -1.77 (Retained Earnings -859.6m / Total Assets 485.6m)
C: -0.00 (EBIT TTM -1.91m / Avg Total Assets 419.9m)
D: -4.55 (Book Value of Equity -859.6m / Total Liabilities 188.8m)
Altman-Z'' Score: -5.45 = D
Beneish M -3.84
DSRI: 0.84 (Receivables 95.5m/68.4m, Revenue 107.5m/64.4m)
GMI: 0.57 (GM 94.87% / 54.09%)
AQI: 0.17 (AQ_t 0.08 / AQ_t-1 0.44)
SGI: 1.67 (Revenue 107.5m / 64.4m)
TATA: -0.27 (NI 105.9m - CFO 238.5m) / TA 485.6m)
Beneish M-Score: -3.84 (Cap -4..+1) = AAA
What is the price of TBPH shares? As of April 06, 2026, the stock is trading at USD 16.02 with a total of 508,782 shares traded.
Over the past week, the price has changed by +4.98%, over one month by +17.97%, over three months by -13.03% and over the past year by +90.49%.
Is TBPH a buy, sell or hold? Theravance Biopharma has received a consensus analysts rating of 3.75. Therefor, it is recommend to hold TBPH.
  • StrongBuy: 1
  • Buy: 1
  • Hold: 2
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the TBPH price?
Wallstreet Target Price 16.6 3.6%
Analysts Target Price 16.6 3.6%
TBPH Fundamental Data Overview as of 06 April 2026
P/E Trailing = 7.7767
P/E Forward = 7.485
P/S = 7.6762
P/B = 2.7801
P/EG = -0.05
Revenue TTM = 107.5m USD
EBIT TTM = -1.91m USD
EBITDA TTM = 827k USD
Long Term Debt = 42.7m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 10.9m USD (from shortTermDebt, last quarter)
Debt = 75.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -92.3m USD (from netDebt column, last quarter)
Enterprise Value = 585.1m USD (824.9m + Debt 75.5m - CCE 315.4m)
Interest Coverage Ratio = -0.78 (Ebit TTM -1.91m / Interest Expense TTM 2.46m)
EV/FCF = 2.45x (Enterprise Value 585.1m / FCF TTM 238.5m)
FCF Yield = 40.77% (FCF TTM 238.5m / Enterprise Value 585.1m)
 FCF Margin = 221.9% (FCF TTM 238.5m / Revenue TTM 107.5m)
 Net Margin = 98.54% (Net Income TTM 105.9m / Revenue TTM 107.5m)
Gross Margin = 94.87% ((Revenue TTM 107.5m - Cost of Revenue TTM 5.51m) / Revenue TTM)
Gross Margin QoQ = none% (prev 59.42%)
Tobins Q-Ratio = 1.20 (Enterprise Value 585.1m / Total Assets 485.6m)
Interest Expense / Debt = 0.77% (Interest Expense 583k / Debt 75.5m)
Taxrate = 16.48% (12.0m / 73.1m)
NOPAT = -1.60m (EBIT -1.91m * (1 - 16.48%)) [loss with tax shield]
Current Ratio = 10.93 (Total Current Assets 418.5m / Total Current Liabilities 38.3m)
Debt / Equity = 0.25 (Debt 75.5m / totalStockholderEquity, last quarter 296.7m)
 Debt / EBITDA = -111.6 (out of range, set to none) (Net Debt -92.3m / EBITDA 827k)
 Debt / FCF = -0.39 (Net Debt -92.3m / FCF TTM 238.5m)
Total Stockholder Equity = 230.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 25.22% (Net Income 105.9m / Total Assets 485.6m)
RoE = 46.03% (Net Income TTM 105.9m / Total Stockholder Equity 230.1m)
RoCE = -0.70% (EBIT -1.91m / Capital Employed (Equity 230.1m + L.T.Debt 42.7m))
 RoIC = -0.69% (negative operating profit) (NOPAT -1.60m / Invested Capital 230.1m)
 WACC = 8.49% (E(824.9m)/V(900.4m) * Re(9.21%) + D(75.5m)/V(900.4m) * Rd(0.77%) * (1-Tc(0.16)))
Discount Rate = 9.21% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 3.62%
[DCF] Terminal Value 68.46% ; FCFF base≈238.5m ; Y1≈156.6m ; Y5≈71.6m
[DCF] Fair Price = 27.14 (EV 1.31b - Net Debt -92.3m = Equity 1.40b / Shares 51.5m; r=8.49% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 64.85 | EPS CAGR: 7.82% | SUE: 0.14 | # QB: 0
Revenue Correlation: 79.89 | Revenue CAGR: 39.43% | SUE: -0.97 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.17 | Chg7d=+0.000 | Chg30d=+0.195 | Revisions Net=+1 | Analysts=1
EPS current Year (2026-12-31): EPS=4.40 | Chg7d=+1.997 | Chg30d=+2.710 | Revisions Net=+3 | Growth EPS=+3070.6% | Growth Revenue=-21.2%
EPS next Year (2027-12-31): EPS=1.35 | Chg7d=+0.258 | Chg30d=+1.192 | Revisions Net=+3 | Growth EPS=-69.2% | Growth Revenue=+3.4%
External Resources
Dataroma Stockcircle